Human antibodies to the glucagon receptor and methods of use thereof for lowering blood glucose or ketone levels
First Claim
1. An isolated human antibody or antigen-binding fragment thereof that specifically binds human glucagon receptor (hGCGR), comprising a heavy chain variable region (HCVR) having an amino acid sequence that has at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO:
- 86; and
a light chain variable region (LCVR) having an amino acid sequence that has at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO;
88;
wherein any sequence variability is present only within the one or more framework regions of the HCVR and/or within the one or more framework regions of the LCVR.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
17 Citations
21 Claims
-
1. An isolated human antibody or antigen-binding fragment thereof that specifically binds human glucagon receptor (hGCGR), comprising a heavy chain variable region (HCVR) having an amino acid sequence that has at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO:
- 86; and
a light chain variable region (LCVR) having an amino acid sequence that has at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO;
88;wherein any sequence variability is present only within the one or more framework regions of the HCVR and/or within the one or more framework regions of the LCVR. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
- 86; and
- 16. An isolated human antibody or antigen-binding fragment thereof that specifically binds human glucagon receptor (hGCGR), comprising an HCVR and an LCVR, wherein the HCVR has an amino acid sequence of SEQ ID NO:
- 18. An isolated human antibody or antigen-binding fragment thereof that specifically binds human glucagon receptor (hGCGR), comprising an HCVR and an LCVR, wherein the LCVR has an amino acid sequence of SEQ ID NO:
-
20. An antibody or antigen-binding fragment thereof that competes for specific binding to hGCGR with an antibody or antigen-binding fragment comprising the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) having an amino acid sequence set forth in SEQ ID NO:
- 86; and
the CDRs of a light chain variable region (LCVR) having an amino acid sequence set forth in SEQ ID NO;
88.
- 86; and
-
21. An antibody or antigen-binding fragment thereof that binds the same epitope on hGCGR as an antibody or antigen-binding fragment comprising the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) having an amino acid sequence of SEQ ID NO:
- 86; and
the CDRs of a light chain variable region (LCVR) having an amino acid sequence of SEQ ID NO;
88.
- 86; and
Specification